A claims-based analysis of prostate biopsy episodes when there is no evidence of a cancer diagnosis
Prostate cancer is the second most common cancer among males in the United States, according to the Centers for Disease Control and Prevention. About one in eight males will be diagnosed with prostate cancer during their lifetime. Guidelines recommend clinicians use prostate specific antigen (PSA) as the first screening test, and follow-up tests for elevated PSAs, including biomarkers, imaging, and prostate biopsy. We were commissioned by LynxDx to analyze the cost of prostate biopsy episodes for patients without prostate cancer. This study covers patients with and without potential prostate biopsy-related complications.
This report was commissioned by LynxDx, Inc.
About the Author(s)
Jack Tyson
A claims-based analysis of prostate biopsy episodes when there is no evidence of a cancer diagnosis
Our recent analysis shows how the total cost of care for prostate biopsy episodes varied substantially, based on whether the patient had complications.